MA32968B1 - Composes quinazoline substitues - Google Patents
Composes quinazoline substituesInfo
- Publication number
- MA32968B1 MA32968B1 MA34018A MA34018A MA32968B1 MA 32968 B1 MA32968 B1 MA 32968B1 MA 34018 A MA34018 A MA 34018A MA 34018 A MA34018 A MA 34018A MA 32968 B1 MA32968 B1 MA 32968B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- kinase
- disorder
- substituted quinazoline
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'INVENTION PORTE SUR CERTAINS COMPOSÉS NOUVEAUX, SUR LEURS MÉTHODES DE PRODUCTION ET SUR DES MÉTHODES DE TRAITEMENT OU D'AMÉLIORATION D'UN TROUBLE À MÉDIATION PAR UNE KINASE. PLUS PARTICULIÈREMENT, CETTE INVENTION PORTE SUR DES COMPOSÉS QUINAZOLINE SUBSTITUÉS UTILES EN TANT QU'INHIBITEURS DE KINASE SÉLECTIFS, SUR DES MÉTHODES DE PRODUCTION DE TELS COMPOSÉS ET SUR DES MÉTHODES DE TRAITEMENT OU D'AMÉLIORATION D'UN TROUBLE ENTRAÎNÉ PAR UNE KINASE. EN PARTICULIER, LES MÉTHODES PORTENT SUR LE TRAITEMENT OU L'AMÉLIORATION D'UN TROUBLE ENTRAÎNÉ PAR UNE KINASE COMPRENANT LES MALADIES CARDIO-VASCULAIRES, LE DIABÈTE, LES TROUBLES LIÉS AU DIABÈTE, LES MALADIES INFLAMMATOIRES, LES TROUBLES IMMUNOLOGIQUES, LE CANCER ET LES MALADIES DES YEUX TELLES QUE LES RÉTINOPATHIES OU LA DÉGÉNÉRESCENCE MACULAIRE OU AUTRE MALADIE VITRÉO-RÉTINIENNE ET SIMILAIRE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08360043 | 2008-12-29 | ||
PCT/EP2009/067494 WO2010076238A1 (fr) | 2008-12-29 | 2009-12-18 | Composés quinazoline substitués |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32968B1 true MA32968B1 (fr) | 2012-01-02 |
Family
ID=41735344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34018A MA32968B1 (fr) | 2008-12-29 | 2009-12-18 | Composes quinazoline substitues |
Country Status (23)
Country | Link |
---|---|
US (1) | US8389530B2 (fr) |
EP (1) | EP2381943A1 (fr) |
JP (1) | JP2012514020A (fr) |
KR (1) | KR20110120878A (fr) |
CN (1) | CN102333533A (fr) |
AU (1) | AU2009334869A1 (fr) |
BR (1) | BRPI0924067A2 (fr) |
CA (1) | CA2748319A1 (fr) |
CO (1) | CO6390105A2 (fr) |
CR (1) | CR20110368A (fr) |
DO (1) | DOP2011000209A (fr) |
EA (1) | EA019110B1 (fr) |
EC (1) | ECSP11011204A (fr) |
IL (1) | IL213742A0 (fr) |
MA (1) | MA32968B1 (fr) |
MX (1) | MX2011007064A (fr) |
NI (1) | NI201100134A (fr) |
NZ (1) | NZ593949A (fr) |
PE (1) | PE20120424A1 (fr) |
SG (1) | SG172415A1 (fr) |
TN (1) | TN2011000319A1 (fr) |
WO (1) | WO2010076238A1 (fr) |
ZA (1) | ZA201104777B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201204723A (en) | 2010-06-22 | 2012-02-01 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
WO2014011900A2 (fr) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibiteurs du récepteur du facteur de croissance de fibroblastes |
EP3060560A1 (fr) | 2013-10-25 | 2016-08-31 | Blueprint Medicines Corporation | Inhibiteurs du récepteur du facteur de croissance des fibroblastes |
WO2015108992A1 (fr) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Composés hétérobicycliques et leur utilisation en tant qu'inhibiteurs du récepteur fgfr4 |
KR101715448B1 (ko) * | 2014-07-16 | 2017-03-20 | 주식회사 큐리언트 | 염증성 질환 치료용 화합물 |
PT3237397T (pt) | 2014-12-24 | 2019-02-08 | Gilead Sciences Inc | Compostos de isoquinolina para o tratamento de hiv |
MX2017008520A (es) | 2014-12-24 | 2018-03-01 | Gilead Sciences Inc | Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). |
TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
CN112239459B (zh) * | 2019-07-19 | 2021-11-26 | 中国科学院上海药物研究所 | 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1235815A1 (fr) | 1999-11-22 | 2002-09-04 | Warner-Lambert Company | Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
JP2007509059A (ja) | 2003-10-16 | 2007-04-12 | カイロン コーポレイション | 癌の処置のためのRafキナーゼのインヒビターとしての、2,6−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン |
AU2005231507B2 (en) | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
WO2006024034A1 (fr) | 2004-08-25 | 2006-03-02 | Targegen, Inc. | Composes heterocycliques et methodes d'utilisation |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
CA2600531A1 (fr) | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Composes de pyrimidine et methodes d'utilisation |
WO2006118256A1 (fr) | 2005-04-28 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | Dérivés de 2-aminoquinazoline |
BRPI0606172A2 (pt) | 2005-06-08 | 2009-06-02 | Targegen Inc | métodos e composições para o tratamento de distúrbios oculares |
TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
MX2009006627A (es) * | 2006-12-22 | 2009-08-12 | Novartis Ag | Quinazolinas para la inhibicion de pdk1. |
-
2009
- 2009-12-18 MA MA34018A patent/MA32968B1/fr unknown
- 2009-12-18 AU AU2009334869A patent/AU2009334869A1/en not_active Abandoned
- 2009-12-18 EA EA201101012A patent/EA019110B1/ru not_active IP Right Cessation
- 2009-12-18 CA CA2748319A patent/CA2748319A1/fr not_active Abandoned
- 2009-12-18 NZ NZ593949A patent/NZ593949A/xx not_active IP Right Cessation
- 2009-12-18 MX MX2011007064A patent/MX2011007064A/es active IP Right Grant
- 2009-12-18 SG SG2011047339A patent/SG172415A1/en unknown
- 2009-12-18 BR BRPI0924067A patent/BRPI0924067A2/pt not_active IP Right Cessation
- 2009-12-18 WO PCT/EP2009/067494 patent/WO2010076238A1/fr active Application Filing
- 2009-12-18 PE PE2011001296A patent/PE20120424A1/es not_active Application Discontinuation
- 2009-12-18 JP JP2011544017A patent/JP2012514020A/ja active Pending
- 2009-12-18 US US13/142,333 patent/US8389530B2/en not_active Expired - Fee Related
- 2009-12-18 KR KR1020117017495A patent/KR20110120878A/ko not_active Application Discontinuation
- 2009-12-18 EP EP09799340A patent/EP2381943A1/fr not_active Withdrawn
- 2009-12-18 CN CN2009801575427A patent/CN102333533A/zh active Pending
-
2011
- 2011-06-23 IL IL213742A patent/IL213742A0/en unknown
- 2011-06-27 CR CR20110368A patent/CR20110368A/es not_active Application Discontinuation
- 2011-06-27 TN TN2011000319A patent/TN2011000319A1/fr unknown
- 2011-06-28 ZA ZA2011/04777A patent/ZA201104777B/en unknown
- 2011-06-29 CO CO11081323A patent/CO6390105A2/es not_active Application Discontinuation
- 2011-06-29 NI NI201100134A patent/NI201100134A/es unknown
- 2011-06-29 DO DO2011000209A patent/DOP2011000209A/es unknown
- 2011-07-14 EC EC2011011204A patent/ECSP11011204A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN102333533A (zh) | 2012-01-25 |
BRPI0924067A2 (pt) | 2016-01-26 |
ZA201104777B (en) | 2012-03-28 |
SG172415A1 (en) | 2011-07-28 |
NI201100134A (es) | 2012-03-06 |
US20120004210A1 (en) | 2012-01-05 |
IL213742A0 (en) | 2011-07-31 |
EA019110B1 (ru) | 2014-01-30 |
EA201101012A1 (ru) | 2012-01-30 |
US8389530B2 (en) | 2013-03-05 |
MX2011007064A (es) | 2012-01-20 |
CA2748319A1 (fr) | 2010-07-08 |
KR20110120878A (ko) | 2011-11-04 |
CR20110368A (es) | 2011-12-02 |
JP2012514020A (ja) | 2012-06-21 |
EP2381943A1 (fr) | 2011-11-02 |
AU2009334869A1 (en) | 2011-07-14 |
CO6390105A2 (es) | 2012-02-29 |
WO2010076238A1 (fr) | 2010-07-08 |
TN2011000319A1 (en) | 2012-12-17 |
AU2009334869A2 (en) | 2011-09-29 |
DOP2011000209A (es) | 2011-09-30 |
NZ593949A (en) | 2013-08-30 |
ECSP11011204A (es) | 2011-10-31 |
PE20120424A1 (es) | 2012-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32968B1 (fr) | Composes quinazoline substitues | |
FR21C1031I2 (fr) | Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives | |
BRPI0517733A (pt) | composições compreendendo derivados de scilo-inositol e métodos para tratar transtornos de agregação de proteìna | |
ATE528302T1 (de) | 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind | |
MA32975B1 (fr) | Antagonistes de c5ar | |
ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
MA30337B1 (fr) | Anticorps | |
MA33604B1 (fr) | Composés et compositions en tant qu'inhibiteurs de protéine kinase | |
MA30557B1 (fr) | Composés de pyrrolopyrimidine et leurs utilisations. | |
MA30772B1 (fr) | Composes et compositions utilises en tant qu'inhibiteurs de proteine kinase | |
TW200640443A (en) | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors | |
TW200630356A (en) | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole | |
EA200802167A1 (ru) | Лекарства и применения | |
MA33730B1 (fr) | Procédés de synthèse pour des composés spiro-oxindoles | |
MA32771B1 (fr) | Mutants fgf21 et leurs utilisations | |
BRPI0509391A (pt) | piridonas substituìdos como inibidores de poli(adp-ribose) polimerase (parp) | |
MA33716B1 (fr) | Mutants de fgf21 et leurs utilisations | |
MA33534B1 (fr) | Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine | |
MY151191A (en) | Novel antibodies | |
TN2009000323A1 (en) | Modulators of sclerostin binding partners for treating bone-related disorders | |
MA47392B1 (fr) | Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques | |
MX2009012625A (es) | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. | |
SG166827A1 (en) | Aminopyrimidines useful as kinase inhibitors | |
MA30983B1 (fr) | Composes chimiques et leurs utilisations | |
MA33566B1 (fr) | Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux |